EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.

Zubeyir Salis, Simona Truglia iD, Oliver Distler iD, Gábor Kumánovics, Gianluca Moroncini, David Launay, Silvia Bellando-Randone, Gonçalo Boleto iD, Nicoletta Del Papa iD, Ana Maria Gheorghiu, Duygu Temiz Karadag iD, Zguro Batalov und 3 weitere

Arthritis Care & Research · 11.11.2026

DOI: 10.1002/acr.80205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 11.11.2026. Verfasst von Zubeyir Salis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Experimental Medicine of the Heart and Muscles (PhyMedExp), University of Montpellier, INSERM U1046, CNRS UMR, 9214, Mon…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to estimate whether adding oral glucocorticoids to ILD‐modifying therapy improves 12‐month lung outcomes in systemic sclerosis‐associated interstitial lung disease (SSc‐ILD).

Methods

We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc‐ILD initiated an eligible ILD‐modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone‐equivalent dose ≤20 mg/day). Follow‐up ended at the visit closest to 12 months within a 9 to 15‐month window. The primary outcome was the between‐group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules.

Results

Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD‐modifying therapy and 258 (58.2%) received ILD‐modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12‐month FVC. The adjusted mean difference in FVC change was ‐2.10 percentage points (95% CI ‐4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated‐weight sensitivity analysis.

Conclusion

Adding oral glucocorticoids to ILD‐modifying therapy was not associated with improved 12‐month FVC in SSc‐ILD. Secondary outcomes were sparse and should be interpreted cautiously. image

Autor:innen und Institutionen

  • Department of Physiology and Experimental Medicine of the Heart and Muscles (PhyMedExp), University of Montpellier, INSERM U1046, CNRS UMR, 9214, Montpellier, France.
  • Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary.
  • Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.
  • Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France; CHU, Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladi…

ORCID-Profile: Simona Truglia, Oliver Distler, Gonçalo Boleto, Nicoletta Del Papa, Duygu Temiz Karadag, Michele Iudici

Zitieren

APA

Salis, Z., Truglia, S., Distler, O., Kumánovics, G., Moroncini, G., Launay, D., Bellando-Randone, S., Boleto, G., Del Papa, N., Gheorghiu, A. M., Karadag, D. T., Batalov, Z., Szucs, G., Iudici, M., & EUSTAR collaborators (2026). Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database. Arthritis Care & Research. https://doi.org/10.1002/acr.80205

Vancouver

Salis Z, Truglia S, Distler O, Kumánovics G, Moroncini G, Launay D, et al. Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database. Arthritis Care & Research. 2026. doi:10.1002/acr.80205

BibTeX
@article{Salis2026,
  author = {Salis, Zubeyir and Truglia, Simona and Distler, Oliver and Kumánovics, Gábor and Moroncini, Gianluca and Launay, David and Bellando-Randone, Silvia and Boleto, Gonçalo and Del Papa, Nicoletta and Gheorghiu, Ana Maria and Karadag, Duygu Temiz and Batalov, Zguro and Szucs, Gabriella and Iudici, Michele and EUSTAR collaborators, EUSTAR collaborators},
  title = {Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database},
  journal = {Arthritis Care & Research},
  year = {2026},
  doi = {10.1002/acr.80205}
}
Kostenlos starten →